Filing Flows › Gilead Sciences (GILD) › Q2 2026 › vs Q1 2026
Gilead Sciences (GILD) Q2 2026 vs Q1 2026 (quarter over quarter)
Gilead Sciences's revenue rose $843M (+12%) from $7.0B in Q1 2026 to $7.8B in Q2 2026.
Gilead Sciences, Q2 2026: revenue $7.8B (+10% year over year), operating margin -133.2%, net loss $10.5B, operating cash flow $3.6B. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $7.8B | $7.0B | $843M | +12% |
| Other income, net | $140M | −$6.0M | $146M | — |
| Net loss | $10.5B | −$2.0B | $12.5B | — |
| Costs & expenses | $18.4B | $7.0B | $11.5B | +165% |
| Operating costs | $18.2B | $4.4B | $13.8B | +316% |
| Income tax | $242M | $559M | −$317M | -57% |
| Cost of revenue | $1.6B | $1.4B | $134M | +9% |
| Research & development | $1.8B | $1.4B | $392M | +29% |
| SG&A | $1.9B | $1.5B | $470M | +32% |
| Other operating costs | $12.9B | $106M | $12.8B | 122× |
| Operating cash sources | $14.1B | $523M | $13.5B | 27× |
| Depreciation | $98.0M | $93.0M | $5.0M | +5% |
| Share-based compensation | $231M | $218M | $13.0M | +6% |
| Working capital & other | $13.7B | $212M | $13.5B | 65× |
| Net loss absorbed | $10.5B | −$2.0B | $12.5B | — |
| Operating cash flow | $3.6B | $2.5B | $1.0B | +40% |
Questions
How much did Gilead Sciences's revenue grow quarter over quarter in Q2 2026?
Gilead Sciences's revenue rose $843M (+12%) from $7.0B in Q1 2026 to $7.8B in Q2 2026.